2. Search Result
Search Result
Results for "

A549 lung carcinoma

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

2

Fluorescent Dyes

2

Biochemical Assay Reagents

2

Peptides

3

Inhibitory Antibodies

6

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13902
    Berzosertib
    Maximum Cited Publications
    24 Publications Verification

    VE-822; VX-970; M6620

    		 ATM/ATR Apoptosis STING Caspase Infection Metabolic Disease Cancer
    Berzosertib (VE-822) is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .
    Berzosertib
  • HY-162307
    Nrf2 degrader 1

    		PROTACs Keap1-Nrf2 Cancer
    Nrf2 degrader 1 (compound 1) is a PROTAC Nrf2 degrader with a DC50 of 0.1-1 μM in huH1 cells. Nrf2 degrader 1 inhibits cancer cells growth for A549 and LK-2 cells with IC50 values of 100 nM and 40 nM, respectively. Nrf2 degrader 1 can be used for the study of liver cancer, non-small cell lung cancer (NSCLC) and squamous cell carcinoma of lung cancer .
    Nrf2 degrader 1
  • HY-P990957
    Ficerafusp alfa

    BCA-101; FMAB2

    		 EGFR TGF-beta/Smad Inflammation/Immunology Cancer
    Ficerafusp alfa (BCA-101) is a bispecific antibody targeting EGFR and TGFβ, with a Kd of 2.58 nM against EGFR and a Kd of 61.3 nM against TGFβ1. Ficerafusp alfa binds to EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against EGFR-positive tumor cells. Ficerafusp alfa sequesters TGFβ via its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and differentiation of inducible regulatory T cells. Ficerafusp alfa is applicable to research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer .
    Ficerafusp alfa
  • HY-P11099
    Cys-LT7

    		Transferrin Receptor Neurological Disease Cancer
    Cys-LT7 is a transferrin receptor (TfR)-targeting peptide ligand. Cys-LT7 binds to a TfR site distinct from endogenous transferrin, mediates conjugated Doxorubicin (HY-15142A) delivery to TfR-overexpressed tumor cells, and exhibits low toxicity to TfR-low-expressed normal cells. Cys-LT7 is an L-configuration peptide susceptible to proteolytic enzymes, leading to poor biostability in peptide-drug conjugates. Cys-LT7 can be used for the research of glioblastoma, hepatocellular carcinoma, lung carcinoma .
    Cys-LT7
  • HY-126437I
    Poly-L-lysine hydrobromide (MW 1000-5000)

    		Biochemical Assay Reagents DNA Alkylator/Crosslinker Amino Acid Derivatives Cancer
    Poly-L-lysine hydrobromide (MW 1000-5000) is a homopolymer of L-lysine and a polycationic non-viral gene delivery vector. Poly-L-lysine hydrobromide (MW 1000-5000) forms complexes with plasmid DNA. Poly-L-lysine hydrobromide (MW 1000-5000) is applicable to relevant research on lung cancer .
    Poly-L-lysine hydrobromide (MW 1000-5000)
  • HY-D1078
    5(6)-Carboxy-2',7'-dichlorofluorescein diacetate

    		Fluorescent Dye Reactive Oxygen Species (ROS) P-glycoprotein Others
    5 (6)-Carboxy-2',7'-dichlorofluorescein diacetate is a fluorescein-based reactive oxygen species (ROS) probe and also a MRP2 substrate. 5 (6)-Carboxy-2',7'-dichlorofluorescein diacetate serves as a substrate for intracellular esterases, which cleave its acetate groups to generate a fluorescent product capable of detecting intracellular ROS. 5 (6)-Carboxy-2',7'-dichlorofluorescein diacetate is ATP-dependent and is transported via a single MRP2 binding site; it competes with LTC4 for MRP2 binding sites and inhibits MRP2-mediated LTC4 transport (Ex/Em = 496/525 nm) .
    5(6)-Carboxy-2',7'-dichlorofluorescein diacetate
  • HY-N2135
    Puerarin 6''-O-Xyloside

    		Apoptosis Caspase Bcl-2 Family Tyrosinase Metabolic Disease Cancer
    Puerarin 6''-O-Xyloside is one of the major iso-flavones found in P. lobata. Puerarin 6''-O-Xyloside inhibits cancer cells proliferation, induces apoptosis by upregulating cleaved caspase-3, 7, 9, Bax and downregulating Bcl-2 levles and inhibits tumor growth in mice. Puerarin 6''-O-Xyloside has anti-osteoporotic activity in ovariectomized mice. Puerarin 6''-O-Xyloside inhibits mushroom tyrosinase with an IC50 of 513.8 μM. Puerarin 6''-O-Xyloside can be used for the research of human lung carcinoma, osteoporosis, melanosis and melanomar .
    Puerarin 6''-O-Xyloside
  • HY-P2282
    APTSTAT3-9R
    1 Publications Verification

    		 STAT Cancer
    APTSTAT3-9R, a specific STAT3-binding peptide, inhibits STAT3 activation and downstream signaling by specifically blocking STAT3 phosphorylation. APTSTAT3-9R exerts antiproliferative effects and antitumor activity .
    APTSTAT3-9R
  • HY-108016
    Peruvoside

    Encordin

    		 Src PI3K JNK STAT EGFR Apoptosis Autophagy Cancer
    Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib .
    Peruvoside
  • HY-P991196
    Anti-CD24 Antibody (SWA11)

    		Transmembrane Glycoprotein Cancer
    Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody targeting CD24, with high affinity and specificity for CD24-expressing tumor cells. Anti-CD24 Antibody (SWA11) triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) is applicable to cancer-related research such as lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Anti-CD24 Antibody (SWA11)
  • HY-N8420
    Thalifoline

    		Fungal Infection Cancer
    Thalifoline is an isoquinoline alkaloid. Thalifoline exerts cytotoxic effects on cancer cells. Thalifoline inhibits the growth of Fusarium oxysporum f. sp. lycopersici. Thalifoline can be used in research related to lung adenocarcinoma, colon cancer, oral epidermoid carcinoma, and fungal infections .
    Thalifoline
  • HY-B1272A
    Desipramine

    		Adrenergic Receptor ERK JNK p38 MAPK NF-κB AP-1 Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism TNF Receptor Neurological Disease Inflammation/Immunology Cancer
    Desipramine is a first-generation tricyclic antidepressant. Desipramine selectively binds to norepinephrine transporter and blocks neuronal norepinephrine reuptake. Desipramine activates MAPK signaling via ERK1/2, JNK, and p38, represses NF-κB and AP-1 activity, and induces apoptosis via ROS elevation, mitochondrial membrane potential reduction, and intracellular calcium increase. Desipramine also shows anyi-inflammatory activity, inhibiting TNF-α production. Desipramine can be used for the research of hepatocellular cancer, inflammation, and neurological diseases .
    Desipramine
  • HY-121255
    (-)-Cryptopleurine

    (R)-Cryptopleurine; NSC 19912

    		 TMV Cancer
    (–)-Cryptopleurine is an alkaloid that has been found in Lauraceae and has diverse biological activities. It inhibits the growth of human A375 melanoma, A431 epidermoid carcinoma, A549 lung, MES-SA uterine sarcoma, and MCF-7 breast cancer cells (IC50=3 nM for all).2 (–)-Cryptopleurine inhibits hypoxia-induced gene expression in a hypoxia response element (HRE) reporter assay (IC50=8.7 nM).3 (–)-Cryptopleurine (500 μg/mL) prevents lesion formation in tobacco (N. tabacum) plants infected with tobacco mosaic virus (TMV). It also inhibits protein synthesis by yeast and mammalian ribosomes.
    (-)-Cryptopleurine
  • HY-W718423
    Isodecyl diphenyl phosphate

    IDPP

    		 DNA/RNA Synthesis MDM-2/p53 Cancer
    Isodecyl diphenyl phosphate (IDPP) is a flame retardant. Isodecyl diphenyl phosphate induces cytotoxicity, DNA damage, mitochondrial dysfunction and oxidative stress in cancer cells, and mediates DNA damage and cell cycle arrest via a p53-dependent pathway .
    Isodecyl diphenyl phosphate
  • HY-149842
    AKT-IN-18

    		Akt Apoptosis Cancer
    AKT-IN-18, an inhibitor of Akt, inhibits Akt with an IC50 of 69.45 μΜ in A549 cells. AKT-IN-18 induces apoptosis and can be used in non-small cell lung cancer study .
    AKT-IN-18
  • HY-N6252
    Gypenoside XLVI
    1 Publications Verification

    		 Others Cancer
    Gypenoside XLVI is one of the major dammarane-type triterpenoid saponins from Gynostamma pentaphallum . Gypenoside XLVI has a tetracyclic triterpene structure and possess potent non-small cell lung carcinoma A549 cell inhibitory activity .
    Gypenoside XLVI
  • HY-W778423
    [Pt(DACH)(OH)2(ox)]

    Dihydroxy Oxaliplatin-Pt(IV)

    		 Drug Intermediate Cancer
    [Pt(DACH)(OH)2(ox)] is a Pt(IV) derivative of Oxaliplatin (HY-17371) with two axial hydroxido ligands, used as a precursor for synthesizing Pt(IV)-HDAC inhibitor prodrugs. [Pt(DACH)(OH)2(ox)] exerts cytotoxic activity against human cancer cells and accumulates in cancer cells for nuclear internalization and nuclear DNA platination. [Pt(DACH)(OH)2(ox)] can be used for the research of lung carcinoma, breast carcinoma, pancreatic carcinoma, colon carcinoma .
    [Pt(DACH)(OH)2(ox)]
  • HY-158058
    WYJ-2

    		Toll-like Receptor (TLR) Pyroptosis Inflammation/Immunology Cancer
    WYJ-2 is a selective agonist for toll-like receptor 2/1 (TLR2/1) with EC50 of 18.57 nM in human TLR2 and TLR1 transient-cotransfected HEK 293T cells. WYJ-2 induces pyroptosis and exhibits anticancer activity against non-small cell lung cancer (NSCLC) .
    WYJ-2
  • HY-161618
    MJ04

    		JAK EGFR PI3K IGF-1R GSK-3 Inflammation/Immunology Endocrinology
    MJ04 is a selective inhibitor for Janus Kinase 3 (JAK 3) with an IC50 of 2.03 nM. MJ04 inhibits T cell differentation and inhibits the proinfammatory cytokines in Lipopolysaccharides (HY-D1056)‑induced macrophages. MJ04 exhibits good pharmacokinetic characters in mice, promotes hair growth in DHT-induced androgenetic alopecia (AGA) in athymic mice model, without significant toxicity (LD50 >2 g/kg) .
    MJ04
  • HY-162721
    Anticancer agent 242

    		Biochemical Assay Reagents Cancer
    Anticancer agent 242 (7) possesses anticancer activity in A2780 (IC50 = 0.24 μM, ovarian adenocarcinoma), A2780cis (IC50 = 0.45 μM, resistant derivative of A2780), CCD18Co (IC50 = 0.59 μM, non-malignant human fibroblasts), A549 (IC50 = 0.32 μM, lung carcinoma), HT29 (IC50 = 0.26 μM, colorectal adenocarcinoma), and MCF7 (IC50 = 0.55 μM, breast adenocarcinoma) .
    Anticancer agent 242
  • HY-156033
    EGFR-IN-88

    		EGFR Apoptosis Cancer
    EGFR-IN-88 (Compound 4i) is an EGFR inhibitor (IC50: 87 nM). EGFR-IN-88 shows cytotoxicity against A549 cell with an IC50? of 3.902? μM. EGFR-IN-88 can induce cell apoptosis .
    EGFR-IN-88
  • HY-18333
    EG00229

    		VEGFR Cancer
    EG00229 is an inhibitor for VEGF-A and NRP1 interaction with an IC50 of 8 μM. EG00229 inhibits the migration of HUVECS and the phosphorylation of VEGFR2 in endothelial cells. EG00229 exhibits cytotoxicity in cancer cell A549 .
    EG00229
  • HY-163381
    Antiproliferative agent-48

    		Drug Intermediate Cancer
    Antiproliferative agent-48 (compound PC-A1) shows selective antiproliferative activity against triple-negative breast cancer (TNBC) cells .
    Antiproliferative agent-48
  • HY-149840
    Antitumor agent-113

    		Apoptosis Cancer
    Antitumor agent-113 shows cytotoxic effects on A549 cells with IC50 value of 46.60 μM and induces apoptosis. Antitumor agent-113 can be used in non-small cell lung cancer study .
    Antitumor agent-113
  • HY-149486
    FGFR1 inhibitor 7

    		FGFR Cancer
    FGFR1 inhibitor 7 (compound 5) is an inhibitor of FGFR1 Tyrosine Kinase with IC50 value of 0.33 nM. FGFR1 inhibitor 7 shows broad-spectrum cytotoxicity agasinst human cancer cell lines, and inhibits MOLT3 cells with IC50 of 2.1 μM .
    FGFR1 inhibitor 7
  • HY-177482
    Pro-PTX

    		Drug Intermediate Neurological Disease Cancer
    Pro-PTX is a Pd-sensitive Paclitaxel (HY-B0015) prodrug with anticancer activity. Pro-PTX triggers intramolecular cyclization via Pd-catalyzed depropargylation to release active Paclitaxel (HY-B0015) and a non-toxic byproduct. Pro-PTX exhibits low cytotoxicity and antiproliferative activity in cancer cells and non-cancerous human cerebrovascular pericytes. Pro-PTX is applicable for research related to non-small cell lung cancer, glioblastoma and lung cancer .
    Pro-PTX
  • HY-W353474
    iso-Dehydrozingerone

    		Drug Derivative Cancer
    iso-Dehydrozingerone is a dehydrozingerone analog. iso-Dehydrozingerone exhibits moderate in vitro cytotoxic activity against human tumor cells, with IC50 values of 10.0 μg/mL, 8.2 μg/mL and >10 μg/mL against human nasopharyngeal carcinoma cells, multidrug-resistant nasopharyngeal carcinoma cells and human lung cancer cells, respectively. iso-Dehydrozingerone can be used in studies related to nasopharyngeal carcinoma, multidrug-resistant nasopharyngeal carcinoma and lung cancer .
    iso-Dehydrozingerone
  • HY-183699
    CDK9-IN-52

    		CDK Cancer
    CDK9-IN-52 is a CDK9 inhibitor. CDK9-IN-52 exhibits antiproliferative activity against cancer cells. CDK9-IN-52 can be used in studies related to lung cancer, cervical cancer, and breast cancer .
    CDK9-IN-52
  • HY-183319
    Anticancer agent 320

    		Apoptosis Mitochondrial Metabolism Cancer
    Anticancer agent 320 is a potent broad-spectrum anticancer agent, with low toxicity toward noncancerous cells. Anticancer agent 320 induces cell cycle arrest, DNA double-strand breaks, and early apoptosis. Anticancer agent 320 disrupts mitochondrial function in cancer cells. Anticancer agent 320 inhibits proliferation of lung, colon, and breast cancer cells. Anticancer agent 320 can be used for the research of lung carcinoma, colon carcinoma, breast carcinoma .
    Anticancer agent 320
  • HY-W248121
    Pyrromethene 567

    PM567

    		 Fluorescent Dye Cancer
    Pyrromethene 567 is a commercially available BODIPY dye with a photodynamic cytotoxicity IC50 of 6.8 ± 1.8 μM.Pyrromethene 567 shows cytoplasmic localization and limited cellular uptake in cancer cells.Pyrromethene 567 can be used for the research of lung cancer .
    Pyrromethene 567
  • HY-N3000A
    6-Methoxydihydrosanguinarine hydrochloride

    		JNK IRE1 Akt mTOR YAP Reactive Oxygen Species (ROS) Autophagy Apoptosis Ferroptosis Fungal Caspase DNA/RNA Synthesis Infection Inflammation/Immunology Cancer
    6-Methoxydihydrosanguinarine hydrochloride is an alkaloid with activity across multiple cancer cell types. 6-Methoxydihydrosanguinarine hydrochloride activates IRE1/JNK signaling, blocks Akt/mTOR and PI3K/AKT/mTOR pathways, reduces expression of Cdc25C, CyclinB1, Cdc2, YAP/TAZ, Survivin, GPX4, and EGFR, upregulates IRE1 and DR5, and activates JNK and caspases. 6-Methoxydihydrosanguinarine hydrochloride induces apoptosis, G2/M phase arrest, DNA damage, ROS generation, lipid peroxidation, ferroptosis, autophagy, and suppresses cancer cell growth. 6-Methoxydihydrosanguinarine hydrochloride disruptes the biofilm formation of Candida albicans (C. albicans). 6-Methoxydihydrosanguinarine hydrochloride can be used for the research of non-small cell lung cancer, hepatocellular carcinoma, melanoma, colon carcinoma, ovarian cancer and breast cancer .
    6-Methoxydihydrosanguinarine hydrochloride
  • HY-W727102
    (Z)-8-β-D-Glucopyranosyloxycinnamic acid

    		Others Others
    (Z)-8-β-D-Glucopyranosyloxycinnamic acid is a phenolic glycoside present in the roots of Codonopsis javanica. (Z)-8-β-D-Glucopyranosyloxycinnamic acid exhibits no toxicity against lung cancer, liver cancer and breast cancer cell lines .
    (Z)-8-β-D-Glucopyranosyloxycinnamic acid
  • HY-181567
    METTL3-IN-13

    		METTL3 Cancer
    METTL3-IN-13 is a METTL3 inhibitor. METTL3-IN-13 is applicable to the research of multiple cancers such as hypopharyngeal squamous cell carcinoma and non-small cell lung cancer .
    METTL3-IN-13
  • HY-182785
    Photosensitizer-10

    		Photosensitizer Cancer
    Photosensitizer-10 is a glutathione (GSH)-activatable photosensitizer. Photosensitizer-10 shows minimal photoactivity in the absence of glutathione, and generates a highly active species upon reaction with glutathione to induce photo-cytotoxicity. Photosensitizer-10 exhibits selective photo-cytotoxicity toward cancer cells with elevated intracellular glutathione levels while sparing normal cells. Photosensitizer-10 can be used for the research of cancer, such as lung carcinoma and skin carcinoma .
    Photosensitizer-10
  • HY-181981
    NTPDase/NPP1-IN-1

    		NTPDase Phosphodiesterase (PDE) Cancer
    NTPDase/NPP1-IN-1 is an ectonucleotidase (NTPDase) and nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) inhibitor, with IC50 values of 0.28, 0.92, 0.82 and 0.73 μM against h-NTPDase1, h-NTPDase2, h-NTPDase3 and h-NPP1, respectively. NTPDase/NPP1-IN-1 is a membrane-interacting agent that localizes to the plasma membrane and interacts with cancer cells. NTPDase/NPP1-IN-1 can be used in the research of breast cancer .
    NTPDase/NPP1-IN-1
  • HY-117612
    KS-99

    		Microtubule/Tubulin Akt Cancer
    KS-99 is a dual inhibitor with both tubulin polymerization inhibitory activity and Akt pathway inhibitory activity. KS-99 inhibits cancer cell proliferation and induces cancer cell apoptosis. KS-99 can be used in research related to colorectal cancer, breast cancer, lung epithelial cancer and melanoma .
    KS-99
  • HY-181125
    Pim-1 kinase-IN-16

    		Pim Apoptosis Cancer
    Pim-1 kinase-IN-16 is a potent PIM-1 kinase inhibitor. Pim-1 kinase-IN-16 can inhibit cancer cells proliferation, induce necrosis and late apoptosis. Pim-1 kinase-IN-16 can be used for the research of cancer, such as prostate cancer, colon cancer, lung cancer .
    Pim-1 kinase-IN-16
  • HY-183788
    EGFR-IN-212

    		EGFR Apoptosis Cancer
    EGFR-IN-212 is an EGFR inhibitor with human IC50 values of 1.83 μM. EGFR-IN-212 reduces EGFR mRNA expression and induces apoptosis. EGFR-IN-212 can be used for the research of non-small cell lung carcinoma .
    EGFR-IN-212
  • HY-W035150
    Chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper(I)

    		Biochemical Assay Reagents Cancer
    Chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper(I) (Compound 1) is a NHC copper complex and anticancer agent. Chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper(I) exhibits cytotoxic activity against breast cancer, lung cancer, melanoma, and glioma cells .
    Chloro[1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene]copper(I)
  • HY-182514
    BMMP

    		HIV hnRNP Infection Cancer
    BMMP is an anti-HIV-1 agent and hnRNP M modulator. BMMP modulates hnRNP M function to suppress CD44 mRNA expression. BMMP induces abnormal uncoating of the HIV viral core at the post-entry step. BMMP suppresses migration of TGF-β-stimulated lung carcinoma cells. BMMP suppresses HIV-1 reverse transcription and replication without inhibiting virion release. BMMP exerts anti-HIV-1 activity via a mechanism distinct from CA protein-binding heterocyclic compounds. BMMP can be used for the research of human immunodeficiency virus infection and non-small cell lung cancer .
    BMMP
  • HY-181477
    ERK5-IN-7

    		ERK Apoptosis Bcl-2 Family Caspase Reactive Oxygen Species (ROS) Cancer
    ERK5-IN-7 is an orally active ERK5 inhibitor with an IC50 of 403.4 nM. ERK5-IN-7 directly inhibits ERK5 kinase activity, and downregulates the phosphorylation level and total protein expression of ERK5. ERK5-IN-7 induces Apoptosis (upregulates Bax, downregulates Bcl-2, and induces Caspase-3 cleavage). ERK5-IN-7 induces ROS accumulation. ERK5-IN-7 exhibits anticancer effects against Lewis lung cancer .
    ERK5-IN-7
  • HY-181657
    EGFR-IN-200

    		EGFR TNF Receptor Interleukin Related Apoptosis Cancer
    EGFR-IN-200 is an inhibitor targeting EGFR, TNF-α, and the IL-6/GP130 complex, which potently targets human EGFR (IC50=0.03 μM), TNF-α (IC50=3.1 μM), and the IL-6/GP130 complex (IC50=1.6 μM). EGFR-IN-200 binds to the ATP pocket of EGFR, the trimer interface of TNF-α, and the cytokine-receptor interface of IL-6/GP130, induces G2/M cell cycle arrest, apoptosis, and antiproliferative activity. EGFR-IN-200 exhibits high gastrointestinal absorbability, low BBB permeability, and complies with the Lipinski's rule. EGFR-IN-200 can be used for the research of lung cancer and breast adenocarcinoma .
    EGFR-IN-200
  • HY-181673
    ICD inducer-2

    		Microtubule/Tubulin Apoptosis Bcl-2 Family Caspase PARP Cancer
    ICD inducer-2 is a immunogenic cell death inducer. ICD inducer-2 binds to the colchicine binding site on tubulin to inhibit tubulin polymerization. ICD inducer-2 exhibits broad-spectrum antiproliferative activity across multiple cancer cell lines. ICD inducer-2 inhibits cells migration, causes G2/M phase and induces apoptosis. ICD inducer-2 promotes infiltration of CD4+ and CD8+ T cells into the tumor microenvironment. ICD inducer-2 downregulates antiapoptotic protein Bcl-2, upregulates proapoptotic proteins Bax and Bim-1, and increases cleaved caspase 3, cleaved caspase 9, and cleaved PARP levels. ICD inducer-2 overcomes paclitaxel resistance in xenograft models and achieves tumor growth inhibition. ICD inducer-2 can be used for the research of cancer, such as lung carcinoma .
    ICD inducer-2
  • HY-181080
    TOP1/TDP1-IN-1

    		Topoisomerase DNA/RNA Synthesis Apoptosis Cancer
    TOP1/TDP1-IN-1 is a DNA topoisomerase 1B (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitor with a TDP1 IC50 of 17.8 μM. TOP1/TDP1-IN-1directly suppresses TOP1 catalytic activity without forming a DNA-TOP1 ternary complex, inhibits TDP1-mediated repair of TOP1-induced DNA damage, and exhibits low acute toxicity. TOP1/TDP1-IN-1 disrupts DNA repair pathways, induces apoptosis, suppresses clonogenic growth, and elicits antiproliferative effects in cancer cells. TOP1/TDP1-IN-1 can be used for the research of non-small cell lung cancer, cervical cancer, colon cancer .
    TOP1/TDP1-IN-1
  • HY-13902A
    Berzosertib hydrochloride
    Maximum Cited Publications
    24 Publications Verification

    VE-822 hydrochloride; VX-970 hydrochloride; M6620 hydrochloride

    		 ATM/ATR Apoptosis STING Caspase Neurological Disease Cancer
    Berzosertib (VE-822) hydrochloride is an orally active, CNS-penetrant, and selective ATR kinase inhibitor. Berzosertib hydrochloride blocks ATR kinase activity, abrogates G2/M cell cycle checkpoint, impairs DNA damage repair. Berzosertib hydrochloride induces apoptosis, inhibnits conlony migration, inhibits cell proliferation, and activates cGAS-STING axes in cancer cells. Berzosertib hydrochloride can be used for the research of cancers, such as head and neck squamous cell carcinoma, and colorectal cancer .
    Berzosertib hydrochloride
  • HY-182266
    FBP

    		Mitochondrial Metabolism Apoptosis Reactive Oxygen Species (ROS) DNA/RNA Synthesis Cancer
    FBP is a mitochondria-targeted, selective anticancer agent. FBP induces oxidative stress and mitochondrial dysfunction, leading to Apoptosis. FBP generates ROS and causes double-strand DNA breaks in cancer cells. FBP exhibits cytotoxic efficacy against cancer cells, with cervical cancer cells being the most sensitive. FBP can be used for the research of cervical cancer, lung cancer, melanoma and breast cancer .
    FBP
  • HY-181493
    VEGFR-2-IN-81

    		VEGFR Reactive Oxygen Species (ROS) Apoptosis Cancer
    VEGFR-2-IN-81 is a thiazole-based isoquinolin-1(2H)-one derivative and an VEGFR-2 inhibitor with IC50 of 1.94 μM. VEGFR-2-IN-81 exhibits significant selective cytotoxicity against colorectal cancer cells (IC50 = 7.75 μM). VEGFR-2-IN-81 exerts anti-colorectal cancer effects by inducing apoptosis, elevating intracellular ROS levels and reducing mitochondrial transmembrane potential. VEGFR-2-IN-81 can be used for the research of colorectal cancer, lung cancer, breast cancer, liver cancer .
    VEGFR-2-IN-81
  • HY-P991883
    Metuzumab

    Licartin; Metuximab; Mehuzumab

    		 Apoptosis CDK Caspase Bcl-2 Family Cancer
    Metuzumab (Licartin) is a human-mouse chimeric IgG1 monoclonal antibody targeting CD147. Metuzumab induces Apoptosis, reduces levels of Cyclin D1, full-length Caspase-3, and Bcl-2, and increases Bax expression. Metuzumab enhances the sensitivity of non-small cell lung cancer (NSCLC) cells to Gemcitabine (HY-17026). Metuzumab is applicable for research on hepatocellular carcinoma and non-small cell lung cancer [1] [2].
    Metuzumab
  • HY-181720
    Antitumor agent-214

    		Caspase PARP Apoptosis Cancer
    Antitumor agent-214 is a chalcone analogue with anti-tumor activity. Antitumor agent-214 induces cell cycle arrest and apoptosis in tumor cells, disrupts mitochondrial metabolism, and upregulates the expression of caspase 3, caspase 7 and caspase 9, downregulates PARP1. Antitumor agent-214 can be used for anti-tumor research related to colorectal cancer, breast cancer, lung cancer, and cervical cancer .
    Antitumor agent-214

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: